EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Genetic counselling and testing in pulmonary arterial hypertension: a consensus statement on behalf of the International Consortium for Genetic Studies in PAH

Christina A Eichstaedt, Catharina Belge, Wendy K Chung iD, Stefan Gräf iD, Ekkehard Grünig, David Montani iD, Rozenn Quarck iD, Jair A Tenorio-Castano, Florent Soubrier iD, Richard C Trembath, Nicholas W Morrell, for PAH-ICON associated with the PVRI

European Respiratory Journal · 2023-02 · 61 (2) · 2201471

DOI: 10.1183/13993003.01471-2022 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Respiratory Journal, online erschienen am 27.10.2022. Verfasst von Christina A Eichstaedt und 11 weiteren Autor:innen. Beteiligte Einrichtung: Center for Pulmonary Hypertension, Thoraxklinik Heidelberg gGmbH at Heidelberg University Hospital, Heidelberg, Germany. Hauptthemen laut MEDLINE: Pulmonary Arterial Hypertension, Hypertension, Pulmonary. Die Arbeit wurde bisher 62-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NHLBI NIH HHS, British Heart Foundation, FEDER.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pulmonary arterial hypertension (PAH) is a rare disease that can be caused by (likely) pathogenic germline genomic variants. In addition to the most prevalent disease gene, BMPR2 (bone morphogenetic protein receptor 2), several genes, some belonging to distinct functional classes, are also now known to predispose to the development of PAH. As a consequence, specialist and non-specialist clinicians and healthcare professionals are increasingly faced with a range of questions regarding the need for, approaches to and benefits/risks of genetic testing for PAH patients and/or related family members. We provide a consensus-based approach to recommendations for genetic counselling and assessment of current best practice for disease gene testing. We provide a framework and the type of information to be provided to patients and relatives through the process of genetic counselling, and describe the presently known disease causal genes to be analysed. Benefits of including molecular genetic testing within the management protocol of patients with PAH include the identification of individuals misclassified by other diagnostic approaches, the optimisation of phenotypic characterisation for aggregation of outcome data, including in clinical trials, and importantly through cascade screening, the detection of healthy causal variant carriers, to whom regular assessment should be offered.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary Arterial HypertensionHypertension, PulmonaryHumansGenetic CounselingMutationFamilial Primary Pulmonary HypertensionGenetic TestingBone Morphogenetic Protein Receptors, Type IIGenetic Predisposition to Disease

Substanzen

Bone Morphogenetic Protein Receptors, Type II

Autor:innen und Institutionen

  • Center for Pulmonary Hypertension, Thoraxklinik Heidelberg gGmbH at Heidelberg University Hospital, Heidelberg, Germany.
  • Translational Lung Research Center Heidelberg (TLRC), German Center for Lung Research (DZL), Heidelberg, Germany.
  • Laboratory for Molecular Genetic Diagnostics, Institute of Human Genetics, Heidelberg University, Heidelberg, Germany.
  • Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE), Department of Chronic Diseases and Metabolism (CHROMETA), Clinical Department of Respiratory Diseases, University Hospitals, University of Leuven, Leuve…
  • Department of Pediatrics, Columbia University Irving Medical Center, New York, NY, USA.
  • Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.

ORCID-Profile: Wendy K Chung, Stefan Gräf, David Montani, Rozenn Quarck, Florent Soubrier

Förderung

  • NHLBI NIH HHS
  • British Heart Foundation
  • FEDER
  • Foundation Against PAH
  • Instituto de Salud Carlos III

Zitieren

APA

Eichstaedt, C. A., Belge, C., Chung, W. K., Gräf, S., Grünig, E., Montani, D., Quarck, R., Tenorio-Castano, J. A., Soubrier, F., Trembath, R. C., Morrell, N. W., & for PAH-ICON associated with the PVRI (2023). Genetic counselling and testing in pulmonary arterial hypertension: a consensus statement on behalf of the International Consortium for Genetic Studies in PAH. European Respiratory Journal, 61(2), 2201471. https://doi.org/10.1183/13993003.01471-2022

Vancouver

Eichstaedt CA, Belge C, Chung WK, Gräf S, Grünig E, Montani D, et al. Genetic counselling and testing in pulmonary arterial hypertension: a consensus statement on behalf of the International Consortium for Genetic Studies in PAH. European Respiratory Journal. 2023;61(2):2201471. doi:10.1183/13993003.01471-2022

BibTeX
@article{Eichstaedt2023,
  author = {Eichstaedt, Christina A and Belge, Catharina and Chung, Wendy K and Gräf, Stefan and Grünig, Ekkehard and Montani, David and Quarck, Rozenn and Tenorio-Castano, Jair A and Soubrier, Florent and Trembath, Richard C and Morrell, Nicholas W and for PAH-ICON associated with the PVRI, for PAH-ICON associated with the PVRI},
  title = {Genetic counselling and testing in pulmonary arterial hypertension: a consensus statement on behalf of the International Consortium for Genetic Studies in PAH},
  journal = {European Respiratory Journal},
  year = {2023},
  volume = {61},
  number = {2},
  pages = {2201471},
  doi = {10.1183/13993003.01471-2022}
}
Kostenlos starten →